BMP-7 peptides and methods of use

Patent metadata

Field	Value
Publication number	US-9926357-B2
Application number	US-201113636869-A
Country	US
Kind code	B2
Filing date	Mar 24, 2011
Priority date	Mar 24, 2010
Publication date	Mar 27, 2018
Grant date	Mar 27, 2018

Abstract

The invention relates to truncated BMP-7 growth factors and variants thereof. The invention also relates to methods of making and using the truncated BMP-7 growth factors.

First claim

What is claimed is:

1. A composition comprising
at least one pharmaceutically acceptable carrier,
at least one protease that is not bone morphogenetic protein-1 (BMP-1) or a cysteine protease, and
a peptide consisting of the amino acid sequence of SEQ ID NO: 3, wherein the peptide has osteoinductive activity or chondroinductive activity.

2. A composition comprising at least one pharmaceutically acceptable carrier, at least one protease that is not bone morphogenetic protein-1 (BMP-1) or a cysteine protease, and a peptide consisting of the amino acid sequence of SEQ ID NO: 3, wherein the peptide has osteoinductive activity or chondroinductive activity, and wherein the molar ratio of the at least one protease to the peptide is between 1:1000 and 1000:1.

3. The composition according to claim 1 , wherein the at least one protease is selected from the group consisting of collagenase, clostripain, dispase, trypsin, MMP-13 (matrix metalloproteinase-13), and a mixture thereof.

4. The composition according to claim 1 , wherein the concentration of the peptide is between 10 ng/mL and 200 ng/mL.

5. The composition according to claim 1 , wherein the concentration of the peptide is between 10 ng/mL and 100 ng/mL.

6. The composition according to claim 1 , wherein the concentration of the peptide is between 10 ng/mL and 50 ng/mL.

7. The composition according to claim 1 , wherein the concentration of the peptide is between 10 ng/mL and 25 ng/mL.

8. The composition according to claim 1 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, Ringer's solution, dextrose solution, 5% human serum albumin, dispersion media, coatings, antibacterial and antifungal agents, and isotonic and absorption delaying agents.

9. A composition comprising a pharmaceutically acceptable carrier and a peptide consisting of the amino acid sequence of SEQ ID NO: 3.

10. A method of promoting differentiation of cells into osteoblasts or chondrocytes, the method comprising treating the cells with the composition of claim 1 in an amount effective to promote the differentiation, wherein the cells are progenitor cells, adult stem cells, or induced pluripotent stem cells.

11. The method of claim 10 , wherein the cells are progenitor cells or adult stem cells.

12. The method of claim 11 , wherein the progenitor cells or the adult stem cells are derived from placenta, bone marrow, adipose tissue, blood vessel, amniotic fluid, synovial fluid, synovial membrane, pericardium, periosteum, dura, peripheral blood, umbilical blood, menstrual blood, baby teeth, nucleus pulposus, brain, skin, hair follicle, intestinal crypt, neural tissue, or muscle.

13. The method of claim 10 , wherein the cells are induced pluripotent stem cells.

14. A method of promoting osteogenesis in a tissue, the method comprising treating the tissue with the composition of claim 1 in an amount effective to promote the osteogenesis in the tissue, wherein the tissue is a bone tissue.

15. The method of claim 14 , wherein the osteogenic activity of cells in the treated tissue is greater than the osteogenic activity of cells in untreated tissue.

16. A method of increasing a cellular growth factor activity in cells, the method comprising treating the cells with the composition of claim 1 in an amount effective to increase the cellular growth factor activity in the cells, wherein the cells are progenitor cells, adult stem cells, or induced pluripotent stem cells, and wherein the cellular growth factor activity is osteoinductive activity, chondroinductive activity, or a combination thereof.

17. The method according to claim 16 , wherein the cells are progenitor cells or adult stem cells.

18. The method according to claim 17 , wherein the progenitor cells or the adult stem cells are derived from placenta, bone marrow, adipose tissue, blood vessel, amniotic fluid, synovial fluid, synovial membrane, pericardium, periosteum, dura, peripheral blood, umbilical blood, menstrual blood, baby teeth, nucleus pulposus, brain, skin, hair follicle, intestinal crypt, neural tissue, or muscle.

19. The method according to claim 16 , wherein the cells are induced pluripotent stem cells.

20. The method according to claim 16 , wherein the at least one protease comprises two or more proteases.

21. The method according to claim 20 ,
wherein the two or more proteases comprise: (a) a first protease selected from the group consisting of collagenase, clostripain, dispase, trypsin, MMP-13 (matrix metalloproteinase-13), and a mixture thereof, and (b) a second protease selected from the group consisting of collagenase, clostripain, dispase, trypsin, MMP-13 (matrix metalloproteinase-13), and a mixture thereof, and
wherein the first and second proteases are different.

22. The method according to claim 16 , wherein the at least one protease is collagenase.

23. A method of increasing a cellular growth factor activity in cells, the method comprising treating the cells with the composition of claim 9 , wherein the cells are progenitor cells, adult stem cells, or induced pluripotent stem cells, and wherein the cellular growth factor activity is osteoinductive activity, chondroinductive activity, or a combination thereof.

24. A method of growing and/or culturing cells comprising growing and/or culturing cells in vitro in the presence of the composition of claim 1 .

25. The method according to claim 24 , wherein the cells are selected from the group consisting of mesenchymal stem cells, adipose-derived stem cells, embryonic stem cells, progenitor cells, differentiated cells, undifferentiated cells, and induced pluripotent stem cells.

26. A method of making the composition of claim 1 , comprising
preparing said peptide by contacting mature BMP-7 with collagenase under conditions that promote protein cleavage to produce the peptide and harvesting the peptide, and
mixing the peptide with the at least one pharmaceutically acceptable carrier and the at least one protease, whereby the composition of claim 1 is prepared.

27. A method of making the composition of claim 1 , comprising
preparing said peptide by culturing a host cell under conditions suitable for protein expression, wherein the host cell comprises a vector that encodes said peptide,
harvesting the peptide, and
mixing the peptide with the at least one pharmaceutically acceptable carrier and the at least one protease, whereby the composition of claim 1 is prepared.

Assignees

• Qin Xiaofei
• Chen Silvia
• Chen Jingsong
• Clagett James
• Lifenet Health

Inventors

• Qin Xiaofei
• Chen Silvia
• Chen Jingsong
• Clagett James

Classifications

• C07K14/51 Primary

  Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title

• A61K38/48

  acting on peptide bonds (3.4) · CPC title

• A61K38/1875 Primary

  Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title

• C12N9/48

  acting on peptide bonds (3.4) · CPC title

• C12N5/0602

  Vertebrate cells · CPC title